Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Steven W. Pipe, MD, explores the latest developments in hemophilia A treatments and prophylactic therapies, including extended half-life agents and a groundbreaking bispecific antibody.
Explore the sequelae of nonadherence to prophylactic treatment in hemophilia A and discover strategies for enhancing treatment adherence and overcoming challenges through interdisciplinary collaborations.
Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and best practices in mitigating joint bleeds.